Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). - Wikidata - awgldk - TriplyDB

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

http://www.wikidata.org/entity/Q47936662

about

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer Antigen-specific active immunotherapy for ovarian cancer Antigen-specific active immunotherapy for ovarian cancer Antigen-specific active immunotherapy for ovarian cancer A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes.A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma.MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis.Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009 Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.Human papillomavirus 18 as a poor prognostic factor in stage I-IIA cervical cancer following primary surgical treatment.Expression of the glioma-associated oncogene homolog 1 (gli1) in advanced serous ovarian cancer is associated with unfavorable overall survival.Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma.Midkine as a potential diagnostic marker in epithelial ovarian cancer for cisplatin/paclitaxel combination clinical therapy.Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.

P2860

Q22001066-D3C6B17B-30F8-469B-9C2F-5E5CDA188101 Q24193567-4431971D-1C13-45A3-9406-4B237F7FD6D4 Q24240962-76223944-F10C-44A1-AACE-B84A8D572049 Q24242612-54887D6F-C9AA-4F5D-9F3B-7FA16D9B58B9 Q26862558-E5867CDB-A6C8-4596-86CE-62C5D296E950 Q27853128-449C38A7-223D-4AE2-AF87-E153CF169053 Q30424227-E6347C87-3123-4AC0-BCE8-36A02FBE245E Q30505345-3C2E8CFA-5185-4F76-A05B-67B97DC3D3B9 Q30651792-81130B90-75F5-40B8-9404-FF835DF1D9A8 Q33380181-EDDAE19C-F836-41D9-B0EE-7BAD7FD6DD9B Q33387020-6365670E-4C5E-49F5-86A1-8EA6E47649D7 Q33393909-58326170-53E5-4CA3-B6D3-AD13A419FF9D Q33399902-1E44DB8A-52C4-4018-ADB0-4FF7EB9B7D26 Q33420283-8059662B-1A2D-49A8-8963-8241ACCF10E3 Q33439705-63524270-8F23-43BE-AEE7-31AE1139D3CB Q33441139-8486A573-1806-47C2-898E-41EDC21344AD Q33713506-F488A39E-E8E3-4DB9-8F3C-A8E64015CC62 Q33902738-05B0B4D7-E2C5-4AE2-ABB1-C1215B057618 Q34024735-F7E6D9AA-404A-446B-8419-11C45FF57207 Q34041112-2CF6984E-E65A-4968-970A-9814D2B0C02E Q34196183-EE2C8C56-F67A-4D2F-A7DA-358FC7490F4F Q34326476-F164F757-D911-404A-BD8D-8C78459FA339 Q34390396-13F02191-3A17-4ACA-B1C4-ED631D00085A Q34518245-B0BEA4E4-5438-4188-9C0D-325EA8701859 Q34577030-E7150834-ADEE-4D65-8612-C46E6B5CC0C1 Q34653337-4D770A18-A077-4C12-A3F6-232123E9B07E Q34811103-E4F1E6CF-9934-42F2-97B1-2E37C7E48B33 Q35094175-285055C3-E9FF-492C-9C33-EA1F35E66942 Q35402367-507FCAAC-2E05-4840-B519-7D3AF7B47F05 Q35510378-2F4AFC74-3878-4DEF-93DF-F03A31984C68 Q35628323-44512F77-AF26-4D97-8456-9E584158C2B4 Q35629996-A0DA7929-0DBB-4A75-AA01-2740F841C35B Q35653739-B4C3ACC6-56EF-41E0-9208-B9A3272F9E1D Q35671530-88215A55-5093-4AFD-90C0-4C360757DC5C Q35687796-7A6613B2-0911-4EE0-A7D8-CDA14BA98C11 Q35893437-FE7DB074-DD16-4D5B-9BF2-76177F054A3C Q35931270-A9AD28D9-D73A-4B28-AC70-6A4E24509866 Q36229421-41902C03-7AE3-4FE5-8B4A-5A8E1319796C Q36433053-F4D600C9-59A1-4DF7-AA53-D0AB0EF08D12 Q36613525-0AD6C2D6-D85E-4C8E-B264-AD9298FB8BD1

P2860

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

http://www.wikidata.org/entity/Q47936662

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Re: New guidelines to evaluate ...... solid tumors (ovarian cancer).

@en

Re: New guidelines to evaluate the response to treatment in solid tumors

@nl

type

label

Re: New guidelines to evaluate ...... solid tumors (ovarian cancer).

@en

Re: New guidelines to evaluate the response to treatment in solid tumors

@nl

prefLabel

Re: New guidelines to evaluate ...... solid tumors (ovarian cancer).

@en

Re: New guidelines to evaluate the response to treatment in solid tumors

@nl

P1433

Q47936662-1F079870-D37E-42DE-BC99-915F844D95A0

P1476

Q47936662-DA5F922F-8219-4793-BE55-A310685AE2AD

P2093

Q47936662-0CE1ED10-0CB3-4A42-94D2-51402EFE81F0

Q47936662-247E74FB-BA08-4CF0-B60F-626230CC33CA

Q47936662-26593969-6759-4BAF-9402-E7401C0C90C4

Q47936662-57773A51-72CF-4DBD-85E0-4178B756845B

Q47936662-6D9786DE-E603-49F7-B5AF-6A2AEEFA3B3C

Q47936662-98592035-D0D4-4860-BEDE-EAA3ACFA3B3D

Q47936662-A77611AC-B1AC-4F7D-A621-445E651C2608

Q47936662-AC8D7475-8593-4010-A648-6FE405B1744F

Q47936662-C358B01D-BCDF-44C2-A381-FD8FB22B3221

Q47936662-D5EEA209-31B2-4527-8ADC-F56017045FD6

P2860

Q47936662-03F7D4F6-5CDA-4E6F-A2CA-F29E25F58C66

P304

Q47936662-FFF72B5A-528F-493A-9A1C-DF48E86E2A95

P31

Q47936662-2691E196-F1CC-47F3-A20E-28FDD31E82BA

P356

Q47936662-72B0A0BC-E289-47EA-B5D8-40FA13F13D45

P407

Q47936662-9B2DB435-44D9-44B6-ABC6-6C267E8F785B

P433

Q47936662-A339F5D6-03AD-4F5D-A37D-4C3443A4C6CF

P478

Q47936662-BD40A9BE-0C25-4D95-8E59-8ACA8DAE7455

P50

Q47936662-2DF7F68C-DCDD-4D6E-980C-4D334D1A12E7

P577

Q47936662-1BD50AAA-F55A-45FD-9212-6D42B0D895E0

P5875

Q47936662-E70CFD52-2E98-4908-AB7D-607598B96D9A

P698

Q47936662-6659E2C5-EA4A-4225-B86A-389D13A8BEB2

P921

Q47936662-D68BADC1-A85E-4377-837F-DB41791474E8

P356

P1433

Journal of the National Cancer Institute

P1476

Re: New guidelines to evaluate ...... solid tumors (ovarian cancer).

@en

P2093

Anders Jakobsen

http://www.w3.org/2001/XMLSchema#string

Andreas du Bois

http://www.w3.org/2001/XMLSchema#string

Andres Cervantes

http://www.w3.org/2001/XMLSchema#string

Elizabeth Eisenhauer

http://www.w3.org/2001/XMLSchema#string

Eric Pujade-Lauraine

http://www.w3.org/2001/XMLSchema#string

Gordon J S Rustin

http://www.w3.org/2001/XMLSchema#string

Jan Vermorken

http://www.w3.org/2001/XMLSchema#string

Kathryn Greven

http://www.w3.org/2001/XMLSchema#string

Michael Quinn

http://www.w3.org/2001/XMLSchema#string

Satoru Sagae

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

P304

487-488

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJH081

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8675639

http://www.w3.org/2001/XMLSchema#string

P698

15026475

http://www.w3.org/2001/XMLSchema#string

P921